Association of clinical and genetic factors with left ventricular hypertrophy in hypertension among the indigenous population Mountain Shoria

Objective. To determine the association of clinical and genetic factors with the left ventricular hypertrophy among indigenous patients with hypertension living in Mountain Shoria.Design and methods. A clinical-epidemiological study of Mountain Shoria indigenous populations at isolated regions was undertaken. Continuous method surveyed 547 people, consisted of a sample of the adult population (18 years and older). Studied anthropometric data, lipid spectrum of the blood polymorphisms of genes ADRB1 (Ser49Gly, A/G, rs1801252) ADRA2B (I/D), ACE (I/D), eNOS (4a/4b) and MTHFR (C677T, Ala222Val, rs1801133) and their association with left ventricular hypertrophy.Results. The left ventricular hypertrophy in patients with hypertension was detected in 47.3% of the respondents. The odds ratio found among patients with hypertension duration of 5 years with the respondents hypertrophied myocardium 0.5 times lower (38.2%) than people without this disease of the heart - 61.8%, while among those with hypertension long history of more than 10 years, 4.1 times higher: 73.3% vs 26.7%. In a population of Shor hypercholesterolemia and giperbetaholesterinemiya associated with exaggerated myocardial damage. The percentage of smokers in a cohort of patients with hypertensive cardiac disease was (37.8%) and was higher by 2.0 times than in hypertensive patients without left ventricular hypertrophy (22.0%). With the relative risk of hypertension with myocardial damage in a population Shor associated gene ACE I allele. The odds ratio of hypertension to identify patients with cardiac respondents with heterozygous genotype AG ADRB1 gene was 3.0 times higher compared to the surveyed individuals with homozygous genotypes AA and GG.Conclusion. Among Shor risk of hypertension with left ventricular hypertrophy was influenced by factors: prolonged duration of the disease more than 10 years, smoking, hypercholesterolemia, giperbetaholesterinemiya. Installed Association II genotype of ACE gene and gene genotype AG ADRB1s development of left ventricular hypertrophy in patients with arterial hypertension in the population of Shor.

candidate genes, hypertension, Shor, left ventricular hypertrophy

1. Sehestedt T, Jeppesen J, Hansen T.W et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91.

2. Sehestedt T, Jeppesen J, Hansen T.W et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens 2012; 30: 1928-36.

3. Kristensen S.D, Baumgartner H, Casadeiet B et al. Highlights of the 2008 Scientific Sessions of the European Society of Cardiology: J Am Coll Cardiol 2008; 52 (24): 2032-42.

4. Смирнова М.Д., Агеев Ф.Т. Гипертрофия левого желудочка: прогностическое значение, патогенез и возможность обратного развития. Фокус на блокаторы ангиотензиновых рецепторов. Кардиоваскулярная терапия и профилактика 2007; 6 (6): 109-16.

5. Конради А.О.Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка. Артериальная гипертензия. 2005; 11 (2): 105-10.

6. Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: Медиа Медика, 2005; с. 201-217, 596-616.

7. Danlof B, Devereux R.B, Kieldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.

8. Levy D, Salomon M, D'Agostino R.B et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90 (4): 1786-93.

9. Бражник В.А., Затейщиков Д.А., Сидоренко Б.А. Наследственные факторы и гипертрофия левого желудочка. Кардиология. 2003; 43 (1): 78-88.

10. Bianchi G, Ferrari P, Staessen J.A. Adducin Polymorphism: Detection and impact on hypertension and related disorders hypertension. J American Heart Association 2005; 45 (3): 331-40.

11. Wolff B, Grabe H.J, Schluter C et al. Endothelial nitric oxide synthase Glu 298 Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens 2005; 23 (7): 1361-6.

12. Zivко M, Кusec R, GаlesićК. Impact оf аngiоtensin - cоnvertingenzyme geneроlymоrphismоn prоteinuriaandаrteriаl hyреrtensiоn. Antropolоgy 2013; 37 (3): 765-70.

13. Deng A.Y Genetic basis of polygenic hypertension. Human Mol Genet 2007; 16 (2): 195-202.

14. Кishimоtо T. eNОS Glu298Asp роlymоrphism аnd hyреrtensiоn in а cоhоrt study in Jараnese. Preventive Med 2004; 39 (5): 927-31.

15. Prineas R.J, Crow R.S, Zhang Z-M. The Minnesota Code Manual of Electrocardiographic Findings. Standards and Procedures for Measurement in Epidwmiologic and Clinical Trials. Second Edition, New and Enlarged. Springer, London Dordrecht Heidelberg New York, 2010.

16. Devereux R.B, Alonso D.R, Lutas E.M et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am. J Cardiol 1986; 57 (6): 450-8.

17. Lang R.M, Bierig M, Devereux R.B et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.

18. Snapir A, Scheinin M, Groop L.C, Orho-Melander M. The insertion/deletion variation in the 2B-adrenoceptor does not seem to modify the risk for acute myocardial infarction, but may modify the risk for hypertension in sibpairs from families with type 2 diabetes. Cardiovasc Diabetol 2003; 24 (2): 15.

19. Lima J.J, Feng H, Duckworth L et al. Association analyses of adrenergic receptor polymorphisms with obesity and metabolic alterations. Metabolism 2007; 56 (6): 757-65.

20. Salimi S, Firoozrai M, Nourmohammadi I et al. Endothelial nitric oxide synthase gene intron 4 VNTR polymorphism in patients with coronary artery disease in Iran. Indian J Med Res 2006; 124 (6): 683-8.

21. Frigo G, Bertolo O, Roman E et al. Relationship of left ventricular mass with clinic blood pressure measured over a six month period vs. ambulatory blood pressure (abstract). J Hypertens 2000;18 (2): 44.

22. Lewis J, Maron B. Diversity of patterns of hypertrophy in patients with systemic hypertension. Am J Cardiol 1990; 65 (13): 874-81.

23. Кобалава Ж.Д., Котовская Ю.В. Артериальная гипертония: ключи к диагностике и лечению. М.: Фортэ, 2007.

24. Smalcelj A, Puljevic D, Buljevic B et al. Left ventricular hypertrophy in obese hypertensives: is it really eccentric? Coll Antropol 2000; 24 (1): 167-83.

25. Grandi A.M, Zanzi P, Piantanida E et al. Obesity and left ventricular diastolic function: noninvasive study in normotensives and newly diagnosed never - treated hypertensives. Int J Obes Relat Metab Disord 2000; 24 (8): 954-8.

26. Payne J.R, Eleftheriou K.I, James L.E et al. Left ventricular growth response to exercise and cigarette smoking: data from LARGE Heart. Heart 2006; 92 (12): 1784-8.

27. Wende A.R, Symons J.D, Abel E.D. Mechanisms of lipotoxicity in the cardiovascular system. Curr Hypertens Rep 2012; 14: 517-31.

28. Frangogiannis N.G. The immune system and cardiac repair. Pharmacol Res 2008; 58 (2): 88-111.

29. Минушкина Л.О., Затейщиков Д.А., Сидоренко Б.А. Генетические аспекты регуляции эндотелиальной функции при артериальной гипертонии. Кардиология. 2000; 3: 68-71.

30. Schunkert H, Hengstenberg C, Holmer S.R et al. Lack of association between apolymorphism of the aldosteron esynthase gene and left ventricular structure. Circulation 1999; 99: 2255-60.

31. Кобалава Ж.Д., Караулова Ю.Л., Котовская Ю.В. и др. Генетические аспекты гипертрофии левого желудочка. М.: Вестник РУДН. 2002; 4: 21-9.

32. Fox C.S, Heard-Costa N.L, Vasan R.S et al. Genomewide linkage analysis of weight change in the Framingham heart study. J Clin Endocrinol Metab 2005; 15: 3197-201.

33. Penesova A, Cizmarova E, Kvetnansky R et al. Insertion/deletion polymorphism on ACE gene is associated with endothelial dysfunction in young patients with hypertension. Horm Metab Res 2006; 38 (9): 592-7.

34. Glavnik N, Petrovic D. M235T polymorphism of the angiotensinogen gene and insertion/deletion polymorphism of the angiotensin-1 converting enzyme gene in essential arterial hypertension in Caucasians. Folia Biol (Praha) 2007; 53 (2): 69-70.

35. Fatini C, Guazelli R, Manetti P et al. RAS genes influence exercise - induced left ventricular hypertrophy: an elite athletes study. Med Sci Sports Exerc 2000; 32 (11): 1868-72.

36. Fu C, Wang H, Wang S et al. Association of beta 1-adrenergic receptor gene polymorphisms with left ventricular hypertrophy in human essential hypertension. Clin Biochem 2008; 41 (10-11): 773-8.

37. Meyers K.J, Mosley T.H, Fox E et al. Genetic variations associated with echocardiographic left ventricular traitsin hypertensive blacks. Hypertension 2007; 49 (5): 992-99.